-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The H2 receptor inhibitor ranitidine was approved in the United States in 1983.
By inhibiting gastric acid secretion, it is widely used to treat gastritis, gastric ulcer, duodenal ulcer, reflux esophagitis and other diseases
FDA researchers recently investigated the changes in urine NDMA excretion after oral ranitidine
The study was carried out in West Bend, Wisconsin.
18 healthy volunteers conducted this randomized, double-blind, placebo-controlled, crossover clinical trial.
The average age of the participants was 33.
0 years, 9 women, 7 whites, 11 African Americans, and 7 (94%) completed the trial
.
In the non-cured meat diet group, the median urinary excretion of NDMA at 24 hours after taking ranitidine and placebo was 0.
There was no statistically significant difference in the 24-hour urinary excretion of NDMA between ranitidine and placebo.
Studies believe that compared with placebo, oral 300mg ranitidine does not cause an increase in urinary N-nitrosodimethylamine excretion within 24 hours.
Compared with placebo, oral ranitidine at 300 mg does not cause an increase in urine N-nitrosodimethylamine excretion within 24 hours.
Original source:
Jeffry Florian et al.
Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA) A Randomized Clinical Trial.
JAMA Leave a message here
